TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
AMRX

Amneal Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

18.30$ +1.1% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Amneal Pharmaceuticals, Inc. (AMRX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 56.7% of the shares are freely tradable; institutional investors hold 52.2%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 52.2%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 44.1%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 56.7%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 4.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 348Mio.

Largest Shareholders

Institutions

Institutions AMRX
Name Stake (%) Shares Change (%) Date
BlackRock Inc 7.04 24,519,192 +71.5 03/31/2026
TPG GP A, LLC 3.54 12,328,767 +0.0 03/31/2026
Vanguard Portfolio Management, LLC 3.25 11,324,933 +0.0 03/31/2026
Rubric Capital Management LP 3.17 11,037,589 -10.5 03/31/2026
Vanguard Capital Management, LLC 2.18 7,585,034 +0.0 03/31/2026
State Street Corp 1.95 6,794,702 +65.3 03/31/2026
Dimensional Fund Advisors, Inc. 1.66 5,794,263 +1.8 06/30/2026
Morgan Stanley - Brokerage Accounts 1.33 4,637,185 -3.8 03/31/2026

Funds

Funds AMRX
Name Stake (%) Shares Change (%) Date
iShares Core S&P Small-Cap ETF 3.02 10,503,994 +0.0 08/31/2026
Vanguard MStar Total Stk Mkt Idx Invest 1.60 5,586,542 +0.5 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider holdings

Insider holdings AMRX
Person Role Shares Value As of Type
Patel Tushar Bhikhubhai 10% Owner 61,341,678 1,122,552,707 $ Aug 10, 2026 indirect
Patel Chintu Co-CEO 6,381,734 116,785,732 $ Aug 10, 2026 indirect
Patel Chirag K. President & Co-CEO 6,381,734 116,785,732 $ Aug 10, 2026 indirect
Patel Gautam Director 283,632 5,190,466 $ Aug 10, 2026 indirect
Shah Nikita Executive Vice President 253,390 4,637,037 $ Aug 12, 2026 direct
Kiely John Director 200,252 3,664,612 $ Aug 13, 2026 direct
Boyer Andrew S Executive Vice President 193,646 3,543,722 $ Sep 1, 2026 direct
Buchi J Kevin Director 189,021 3,459,084 $ Aug 11, 2026 both
Daly Jason B. EVP, Chief Legal Officer 35,171 643,629 $ Aug 12, 2026 direct

Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.

Insiders

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
Sep 11, 2026 Buchi J Kevin Director Other 20,445 14.45 295,430
Sep 1, 2026 Boyer Andrew S Executive Vice President Other 80,000 0.00
Aug 21, 2026 Boyer Andrew S Executive Vice President Other 152,426 0.00
Aug 13, 2026 Kiely John Director Other 10,000 0.00
Aug 13, 2026 Kiely John Director Sell 50,000 17.64 882,000
Aug 12, 2026 Shah Nikita Executive Vice President Sell 146,403 17.51 2,563,517
Aug 12, 2026 Daly Jason B. EVP, Chief Legal Officer Sell 210,000 17.40 3,654,000
Aug 11, 2026 Daly Jason B. EVP, Chief Legal Officer Sell 6,613 17.70 117,050
Aug 11, 2026 Buchi J Kevin Director Other 168,573 17.18 2,896,084
Aug 10, 2026 Patel Chintu Co-CEO Other 6,381,734
Aug 10, 2026 Patel Gautam Director Other 283,632
Aug 10, 2026 Patel Chirag K. President & Co-CEO Other 6,381,734
Aug 10, 2026 Patel Tushar Bhikhubhai 10% Owner Other 12,763,469

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?